ReviewDrug design, development and therapy2017

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.

Andrea Becciolini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.